FDA approval expands treatment options for people with metastatic breast cancer that expresses minimal levels of HER2.

by Sandra Gordon

Testing for hereditary mutations is increasingly recommended for people with cancer, but recommendations do not always translate into access to testing and appropriate counseling.

by Kate Yandell

Scientists and physicians discussed advances in targeted therapies and immunotherapies, as well as the lessons COVID-19 research has taught to cancer researchers.

by Kevin McLaughlin

A study shows that a blood test for gastrointestinal tumor mutations gave results in a third of the time needed for solid tissue testing. Patients who received the blood test were more likely to enroll in clinical trials.

by Emma Yasinski

Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.

by Marcus A. Banks

A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

by Ashley P. Taylor

Researchers are investigating why certain patients have an exceptional response to a particular drug.

by Bradley Jones

For a small group of pancreatic cancer patients who were able to receive therapies targeting the molecular alterations in their tumors, these matched therapies were associated with longer life.

by Cheryl Platzman Weinstock

The arrival of generic versions of the targeted therapy imatinib only modestly reduced the cost of treating chronic myelogenous leukemia patients, a study finds.

by Anna Azvolinsky

Medical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.

by Anna Azvolinsky